Linezolid in treatment of multidrug-resistant forms of tuberculosis

Abstract

The Federal clinical recommendations on treatment of pulmonary tuberculosis with multidrug-resistanсe to micobacteruim tuberculosis contain of algorhythm of actions to correct negative side effects appearing in the process of chemotherapy after linezolid prescription. According to this algorhythm, if the negative side effects in form of myelosuppression (inhibition of blood development) or neuropathies are developing, administration of linezolid can be abolished, and the drug prescription can be recovered beginning the dose of 300 mg per day after normalization of blood analysis, under blood analysis control, and then with 2-fold increase of oral dose (300 mg twice a day) to prevent repetitive development of negative side effect. In this case, dispensary prescription of linezolid 300 mg is permitted for tuberculosis treatment. In the paper, a comparative analysis of usage of different doses of linezolid for tuberculosis treatment with argumentation to use median (300 mg) doses of linezolid has been done.

Keywords

linezolid / amizolid / tuberculosis / multidrug-resistance / treatment / efficacy / side effects

References

[1] Федеральные методические рекомендации по лечению туберкулеза органов дыхания с множественной и широкой множественной устойчивостью возбудителя / Утв. на X съезде Российского общества фтизиатров 28.05.2015 г. и профильной комиссии по специальности «Фтизиатрия» МЗ РФ 13.11.2015 г. - 3-е изд. - М., 2015. - 68 с. [Federal’niye metodicheskiye rekomendatsii po lecheniyu tuberkulyoza organov dykhaniya s mnozhestvennoi I shirokoi ustoichivostiyu vozbuditelya. Utverzhdeny na X s’ezde Rossiiskogo obshchestva ftiziatrov 28.05.2015 i profil’noi komissii po spetsial’nosti “Ftiziatriya” MZ RF 13.11.2015. 3rd ed. Moscow; 2015. 68 p. (In Russ.)]

[2] Anger HA, Dworkin F, Sharma S, et al. Linezolid use for treatment of multidrug-resistant and extensively drug-resistant tuberculosis, New York City, 2000-06. J Antimicrob Chemother. 2010;65:775-783. doi: 10.1093/jac/dkq017.

[3] Migliori GB, Eker B, Richardson MD, et al. A retrospective TBNET assessment of linezolid safety, tolerability and efficacy in multidrug-resistant tuberculosis. Eur Respir J. 2009;34:387-393. doi: 10.1183/09031936.00009509.

[4] Koh W-J, Kwon OJ, Gwak H, et al. Daily 300 mg dose of linezolid for the treatment of intractable multidrug-resistant and extensively drug-resistant tuberculosis. J Antimicrobial Chemother. 2009;64:388-391. doi:10.1093/jac/dkp171.

[5] Sotgiu G, Centis R, D’Ambrosio L, et al. Efficacy, safety and tolerability of linezolid containing regimens in treating MDR-TB and XDR-TB: systematic review and meta-analysis. Eur Respir J. 2012;40:1430-1442. doi: 10.1183/09031936.00022912.

[6] https://www.theodora.com/drugs/zyvox_injection_zyvox_tablets_zyvox_for_oral_suspension_pharmacia.html.

RIGHTS & PERMISSIONS

Shabanov P.D.